Wells Fargo’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $62 | Hold |
7
| – | – | ﹤0.01% | 6698 |
|
|
2026
Q1 | $51 | Hold |
7
| – | – | ﹤0.01% | 6597 |
|
|
2025
Q4 | $60 | Hold |
7
| – | – | ﹤0.01% | 6493 |
|
|
2025
Q3 | $193 | Hold |
7
| – | – | ﹤0.01% | 6350 |
|
|
2025
Q2 | $91 | Hold |
7
| – | – | ﹤0.01% | 6490 |
|
|
2025
Q1 | $53 | Hold |
7
| – | – | ﹤0.01% | 6445 |
|
|
2024
Q4 | $52 | Sell |
7
-66
| -90% | -$1.51K | ﹤0.01% | 6498 |
|
|
2024
Q3 | $3.9K | Sell |
73
-400
| -85% | -$38.2K | ﹤0.01% | 5962 |
|
|
2024
Q2 | $56.2K | Buy |
473
+331
| +233% | +$45K | ﹤0.01% | 5251 |
|
|
2024
Q1 | $28.9K | Sell |
142
-167
| -54% | -$29.8K | ﹤0.01% | 5464 |
|
|
2023
Q4 | $50.1K | Sell |
309
-367
| -54% | -$62.1K | ﹤0.01% | 5279 |
|
|
2023
Q3 | $65.9K | Sell |
676
-79
| -10% | -$14.6K | ﹤0.01% | 5030 |
|
|
2023
Q2 | $204K | Buy |
755
+746
| +8,289% | +$261K | ﹤0.01% | 4574 |
|
|
2023
Q1 | $3.09K | Hold |
9
| – | – | ﹤0.01% | 6161 |
|
|
2022
Q4 | $3.28K | Sell |
9
-19
| -68% | -$9.48K | ﹤0.01% | 5886 |
|
|
2022
Q3 | $13K | Hold |
28
| – | – | ﹤0.01% | 5582 |
|
|
2022
Q2 | $16K | Hold |
28
| – | – | ﹤0.01% | 5559 |
|
|
2022
Q1 | $17K | Hold |
28
| – | – | ﹤0.01% | 6080 |
|
|
2021
Q4 | $21K | Buy |
28
+2
| +8% | +$1.6K | ﹤0.01% | 6321 |
|
|
2021
Q3 | $26K | Buy |
26
+22
| +550% | +$14.2K | ﹤0.01% | 5875 |
|
|
2021
Q2 | $3K | Sell |
4
-21
| -84% | -$13.5K | ﹤0.01% | 6469 |
|
|
2021
Q1 | $20K | Sell |
25
-389
| -94% | -$391K | ﹤0.01% | 6158 |
|
|
2020
Q4 | $422K | Sell |
414
-84
| -17% | -$58.3K | ﹤0.01% | 4637 |
|
|
2020
Q3 | $286K | Sell |
498
-257
| -34% | -$153K | ﹤0.01% | 4751 |
|
|
2020
Q2 | $437K | Buy |
755
+100
| +15% | +$57.5K | ﹤0.01% | 4419 |
|
|
2020
Q1 | $295K | Buy |
655
+159
| +32% | +$144K | ﹤0.01% | 4426 |
|
|
2019
Q4 | $843K | Buy |
496
+201
| +68% | +$175K | ﹤0.01% | 3974 |
|
|
2019
Q3 | $141K | Buy |
295
+157
| +114% | +$85.1K | ﹤0.01% | 5154 |
|
|
2019
Q2 | $88K | Buy |
138
+103
| +294% | +$74.2K | ﹤0.01% | 5358 |
|
|
2019
Q1 | $28K | Buy |
35
+7
| +25% | +$5.66K | ﹤0.01% | 5445 |
|
|
2018
Q4 | $12K | Hold |
28
| – | – | ﹤0.01% | 5896 |
|
|
2018
Q3 | $19K | Buy |
28
+26
| +1,300% | +$8.38K | ﹤0.01% | 5841 |
|
|
2018
Q2 | $0 | Sell |
2
-109
| -98% | -$47.2K | ﹤0.01% | 6477 |
|
|
2018
Q1 | $64K | Buy |
111
+7
| +7% | +$5.55K | ﹤0.01% | 5482 |
|
|
2017
Q4 | $90K | Buy |
104
+99
| +1,980% | +$95.5K | ﹤0.01% | 5358 |
|
|
2017
Q3 | $5K | Buy |
+5
| New | +$5.01K | ﹤0.01% | 6026 |
|
Other funds holding MTNB
HIW
SIG
Wells Fargo's MTNB Position: Q2 2026 in Review
Wells Fargo held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 7 shares worth $62. The position accounts for ﹤0.01% of the portfolio, ranked #6698.
Wells Fargo first reported a position in MTNB in Q3 2017 and has held it in 36 quarters since. The position peaked at $843K in Q4 2019. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- Wells Fargo held 7 shares of Matinas BioPharma worth $62 as of Q2 2026.
- Wells Fargo left its Matinas BioPharma share count unchanged in Q2 2026.
- Matinas BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6698 holding.
- Wells Fargo first reported a position in Matinas BioPharma in Q3 2017 and has held it in 36 quarters since.
- Wells Fargo's Matinas BioPharma position peaked at $843K in Q4 2019.
- 23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.